These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22701017)

  • 1. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao SD; Miller PD; Woodson GC; Lindsay R; Binkley N; Alam J; Ruff VA; Gallagher ER; Taylor KA
    J Bone Miner Res; 2016 Jul; 31(7):1429-39. PubMed ID: 26841258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.
    Dempster DW; Roschger P; Misof BM; Zhou H; Paschalis EP; Alam J; Ruff VA; Klaushofer K; Taylor KA
    J Bone Miner Res; 2016 Aug; 31(8):1527-35. PubMed ID: 26931279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes.
    Portero-Muzy NR; Chavassieux PM; Bouxsein ML; Gineyts E; Garnero P; Chapurlat RD
    Bone; 2012 Oct; 51(4):714-9. PubMed ID: 22796591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study.
    Dempster DW; Zhou H; Ruff VA; Melby TE; Alam J; Taylor KA
    J Bone Miner Res; 2018 Apr; 33(4):627-633. PubMed ID: 29194749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Recker RR; Marin F; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Farrerons J; Sanz B; Oertel H; Stepan J
    J Bone Miner Res; 2009 Aug; 24(8):1358-68. PubMed ID: 19338452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
    Dobnig H; Sipos A; Jiang Y; Fahrleitner-Pammer A; Ste-Marie LG; Gallagher JC; Pavo I; Wang J; Eriksen EF
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3970-7. PubMed ID: 15840739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.
    Ma YL; Marin F; Stepan J; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Martínez G; Malouf J; Zeng QQ; Wan X; Recker RR
    Bone; 2011 May; 48(5):972-8. PubMed ID: 21262402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Effects of Single and Low-Frequency Repeated Administration of Teriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats.
    Isogai Y; Takao-Kawabata R; Takakura A; Sugimoto E; Nakazono O; Ikegaki I; Kuriyama H; Ishizuya T
    Calcif Tissue Int; 2015 Oct; 97(4):412-20. PubMed ID: 26141479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
    Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
    Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.